On June 25, Everest Medicines fell 5.15% in regular trading, trading at HKD 23.86/share, with turnover of approximately HKD 32.80 million. The decline was triggered by the company's announcement of a patent settlement with Hainan Herui Pharmaceutical.

On June 24, Everest Medicines announced it had reached a patent understanding with Hainan Herui regarding Nefecon (budesonide enteric-coated capsules), its flagship IgA nephropathy treatment. Under the agreement, Hainan Herui's budesonide enteric-coated capsule — approved by China's NMPA in December — will be permitted to launch in mainland China, with Everest Medicines responsible for its commercialization. As Nefecon is the company's core revenue driver, the market interpreted the entry of a first generic as a signal of weakening exclusivity premium.

Notably, major shareholder CBC Group purchased 712,000 shares for approximately HKD 19.2 million between June 16-17 at an average price of HKD 26.99, and has accumulated over 5.163 million shares since December, signaling institutional confidence in the company's long-term prospects.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)